Articles related to Clinical Pharmacology

In comparison to 72% of patients who received placebo, 45% of those who received teplizumab-mzwv (Tzield, Provention Bio) over the course of a median follow-up of 51 months were found to have stage 3 type 1 diabetes. Teplizumab-mzwv appeared to delay the onset of type 1 diabetes by about two years, as the median time from randomization to diagnosis of stage 3 diabetes was 50 months in the teplizumab-mzwv group and 25 months in the placebo group.

The new Moderna bivalent vaccine showed higher antibody development vs BA.4/BA.5 than the original version and also showed activity (although lower) against the new BQ1.1 strain. The Pfizer-BioNTech bivalent vaccine generated 3- to 5-fold higher antibody levels than the original vaccine against BA.4/.5 and 11-fold higher levels vs the newer variants.

The shortage is driven by increased prescribing due to bacterial infection coexisting with RSV infection, and in cases where it is not possible to tell if the patient is experiencing a bacterial or viral URI. Substitute antibiotics to consider include cephalosporins and amoxicillin-clavulanate.

The controversial 2016 CDC opioid guideline for chronic pain is updated and replaced by the new guidance, which addresses acute, subacute, and chronic pain for primary care and other clinicians. Some organizations misapplied the 2016 guideline, which was perceived as imposing strict opioid dose and duration limits. As a result, the guideline authors clarified their recommendations in 2019.

Part 1—Pain Management Fundamentals Following completion of this activity (1.0 AMA PRA Category 1 Credit™, 1.0 AANP credit, 1.0 ACPE credit, 1.0 ANCC credit), the participant should be able to: Explain the importance of comprehensive pain education Outline the fundamental concepts of pain management, such as pain definitions and pain mechanisms. Examine patients who are in pain, including identifying risk factors for substance abuse and addiction. Discuss the various pain-management approaches, including nonpharmacologic and pharmacologic (non-opioid and opioid analgesic) therapies.

According to new information revealed in a study of the AHA’s COVID-19 Cardiovascular Disease Registry, new onset AFib occurs in 5% of patients hospitalized with COVID-19. Patients who developed new-onset AFib experienced longer hospital stays and approximately 45% died during their hospitalization. Atrial fibrillation can directly increase the risk of stroke and prolong hospitalization. It is also an indirect marker of the insult that the heart is experiencing when patients are infected with COVID-19.